LOGEX en Zorg Invest werken vanaf heden onder een gezamenlijke paraplu aan waarde gedreven zorg
DICA feliciteert LOGEX en Zorg Invest met deze stapBekijk artikel
Het HPB heeft onlangs een artikel over de het doel en de resultaten van de DPCA (Dutch Pancreatic Cancer Audit) gepubliceerd: Nationwide prospective audit of pancreatic surgery: design, accuracy, and outcomes of the Dutch Pancreatic Cancer Audit.
Hieronder staat een samenvatting (EN); lees het volledige artikel in HPB (EN).
Auditing is an important tool to identify practice variation and ‘best practices’. The Dutch Pancreatic Cancer Audit is mandatory in all 18 Dutch centers for pancreatic surgery.
Performance indicators and case-mix factors were identified by a PubMed search for ran- domized controlled trials (RCT’s) and large series in pancreatic surgery. In addition, data dictionaries of two national audits, three institutional databases, and the Dutch national cancer registry were evaluated. Morbidity, mortality, and length of stay were analyzed of all pancreatic resections registered during the first two audit years. Case ascertainment was cross-checked with the Dutch healthcare inspectorate and key-variables validated in all centers.
Sixteen RCT’s and three large series were found. Sixteen indicators and 20 case-mix factors were included in the audit. During 2014–2015, 1785 pancreatic resections were registered including 1345 pancreatoduodenectomies. Overall in-hospital mortality was 3.6%. Following pancreatoduode- nectomy, mortality was 4.1%, Clavien–Dindo grade ! III morbidity was 29.9%, median (IQR) length of stay 12 (9–18) days, and readmission rate 16.0%. In total 97.2% of >40,000 variables validated were consistent with the medical charts.
The Dutch Pancreatic Cancer Audit, with high quality data, reports good outcomes of pancreatic surgery on a national level.